SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : NetCurrents NTCS
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Teresa Lo who wrote (4029)11/8/2000 9:20:38 PM
From: Arthur Radley  Read Replies (1) of 8925
 
Teresa,
I'm back again for your excellent TA assistance. The stock is INKP, a small biotech that just received FDA approval in the area of the cancer that causes the second most deaths in the world. That being colon cancer and the current method of preventing is via the early detection by having a colonoscopy. INKP's newly approved drug has a very unique position in this area in that prior to having a colonoscopy, one has to "clean" the colon for proper viewing. Until now the method of doing this was by having the patient drink a near gallon of what might be described as the most horrible tasting concoction ever forced on a human to drink. INKP has solved this issue by developing a pill that can be taken the night before and morning of the test and needless to say...in trials of the drug(VISICOL)the patient preference was nearly 10:1 for the pill as opposed to the "liquid cocktail". I said INKP has a nice niche product, but to give you some perspective on the potential...by 2003 on a worldwide basis,it is expected that there will be 24 million colonoscopies performed on a yearly basis. This number could grow because of the increasing national attention that this dreaded disease is receiving. For example, some might have seen Katie Couric, NBC Today show, and her recent special in which she actually had a colonoscopy performed(for Ms. Couric her attention to this disease has special meaning because she lost her husband to the disease). But enough of the fundamentals of INKP. The stock for the last week or so has traded in a tight band ($9.25 to $9.50) with the $9.50 appearing to be a wall of resistance....does your TA see the potential of breaking out of this range in the near future?
As always...thanks for your analysis!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News